HOXD13 and diffuse large B-cell lymphoma: Pretreatment sPD-1 levels are a predictor of adverse outcomes after dose-dense immunochemotherapy and can predict the risk of disease progression in patients with diffuse large B-cell lymphoma (DLBCL) (82).